InsiderTrades

Form 4 for KNSA Kiniksa Pharmaceuticals International, plc

Accepted 2025-03-14 00:00:00 ET · period of report 2025-03-12 · accession 0001415889-25-008117 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-03-14 2025-03-12 KNSA Megna Michael R CAO M - OptEx $11.10 +9,051 35.6K +34% +$100.5K
D 2025-03-14 2025-03-12 KNSA Megna Michael R CAO S - Sale+OE $22.45 -9,051 26.5K -25% -$203.2K
D 2025-03-14 2025-03-12 KNSA Megna Michael R CAO M - OptEx $0.00 -9,051 13.8K -40% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Class A Ordinary Share 2025-03-12 M A 9,051 $11.10 35,579 D — —
2 Common Class A Ordinary Share 2025-03-12 S D 9,051 $22.45 26,528 D — — (F2) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $22.45 and $22.465. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
3 Derivative Share Option 2025-03-12 M D 9,051 $0.00 13,763 D $11.10 · — to 2032-04-06 9,051 Class A Ordinary Share (F3) The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022.